Summary:
A phase 1 first in human, randomized, double blind, sponsor open, placebo-controlled, single- and multiple dose escalation, parallel group study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of pf-07242813 in healthy participants and participants with atopic dermatitis.
Qualified Participants Must:
• Age 18 to 65 years old
• BMI between 17.5 and 40
• Have been diagnosed with Eczema (Atopic Dermatitis) for at least one year
Qualified Participants May Receive:
Compensation up to $3100.00